IGF-1 and PTEN regulate the proliferation and invasiveness of colon cancer cells through opposite effects on PI3K/Akt signalling

Archives of Medical Science

Volumn 5, Issue 2, 2009, Pages 195-206

  Ma, Jiachi ^a   Sawai, Hirozumi ^a   Matsuo, Yoichi ^a   Yasuda, Akira ^a   Ochi, Nobuo ^a   Takahashi, Hiroki ^a   Wakasugi, Takehiro ^a   Funahashi, Hitoshi ^a   Sato, Mikinori ^a   Takeyama, Hiromitsu ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

AP 1; Colorectal cancer; IGF 1; PTEN

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER INVASION; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA FLANKING REGION; DOWN REGULATION; DOWNSTREAM PROCESSING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; KNOCKOUT GENE; METASTASIS POTENTIAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 70349696389     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998; 102: 227-34.
2. Akouchekian M, Houshmand M, Hemati S, Shafa M. Occurrence of large-scale mitochondrial DNA deletions in human colorectal cancer. Arch Med Sci 2008; 4: 249-53.
3. Akouchekian M, Houshmand M. Mitochondrial haplogroup analysis in colorectal cancer: identification of a high-risk population. Arch Med Sci 2008; 4: 397-400.
4. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
5. Labianca R, Pessi MA, Zamparelli G. Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy. Drugs 1997; 53: 593-607.
6. Funahashi H, Sawai H, Yasuda A, et al. Glial cell line-derived neurotrophic factor enhances the invasive ability of pancreatic cancer cells by regulating urokinase-type plasminogen activator and matrix metalloproteinase. Arch Med Sci 2007; 3: 323-9.
7. Sawai H, Yasuda A, Ochi N, et al. TGF-beta regulates invasive behavior of human pancreatic cancer cells by controlling Smad expression. Arch Med Sci 2007; 3: 185-91.
8. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/ Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
9. Myers MP, Stolarov JP, Eng C, et al. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997; 94: 9052-57.
10. Zhang X, Jin B, Huang C. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 2007; 7: 305-16.
11. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-7.
12. Sun H, Lesche R, Li DM, et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 1999; 96: 6199-204.
13. Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci USA 1998; 95: 15406-11.
14. Furnari FB, Lin H, Huang HS, Cavenee WK. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 1997; 94: 12479-84.
15. Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat 2000; 16: 109-22.
16. Dahia PL. PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 2000; 7: 115-29.
17. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124-9.
18. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989; 10: 68-91.
19. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-1 receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997; 1332: F105-26.
20. De Meyts P, Wallach B, Christoffersen CT, et al. The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 1994; 42: 152-69.
21. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-20.
22. Lahm H, Amstad P, Wyniger J, et al Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-1l-mediated autocrine loop. Int J Cancer 1994; 58: 452-9.
23. Freier S, Weiss O, Eran M, et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 1999; 44: 704-8.
24. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-33.
25. Yang SY, Sales KM, Fuller BJ, Seifalian AM, Winslet MC. Inducing apoptosis of human colon cancer cells by an IGF-1 D domain analogue peptide. Mol Cancer 2008; 7: 17.
26. Wagner EF. AP-1 - Introductory remarks. Oncogene 2001; 20: 2334-5.
27. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: E131-6.
28. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol Med 2003; 9: 36-41.
29. Kundu JK, Surh YJ. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 2004; 555: 65-80.
30. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998; 50: 151-96.
31. Sato M, Narita T, Kimura N, et al. Interaction between human cancer cells and cultured murine endothelial cells, and its relationship with matastatic potential. Int J Oncology 1997; 10: 1173-8.
32. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999; 91: 151-6.
33. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-5.
34. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998; 95: 13513-8.
35. Weng LP, Smith WM, Dahia PL, et al. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 1999; 59: 5808-14.
36. Guanti G, Resta N, Simone C, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet 2000; 9: 283-7.
37. Cantley LC, Neel BG. New insights into tumor suppression. PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-5.
38. Goel A, Arnold CN, Niedzwiecki D, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64: 3014-21.
39. Li YL, Tian Z, Wu DY, Fu BY, Xin Y. Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol 2005; 11: 285-8.
40. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
41. Kim S, Domon-Dell C, Wang Q, et al. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology 2002; 123: 1163-78.
42. Saito Y, Gopalan B, Mhashilkar AM, et al. Adenovirus-mediated PTEN treatment combined with caffeine produces a synergistic therapeutic effect in colorectal cancer cells. Cancer Gene Ther 2003; 10: 803-13.
43. Franke TF, Kaplan DR, Cantley LC. P13K: downstream AKTion blocks apoptosis. Cell 1997; 88: 435-7.
44. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9: 345-9.
45. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-1R expression in prostate cancer cells. Oncogene 2004; 23: 786-94.
46. Yi HK, Kim SY, Hwang PH, et al. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 2005; 330: 760-7.
47. Kang-Park S, Lee YI, Lee YI. PTEN modulates insulin-like growth factor II (IGF-1l)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-1l expression in hepatoma cells. FEBS Lett 2003; 545: 203-8.
48. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene 2001; 20: 2401-12.